MIKHAIL BLAGOSKLONNY’S VIEW ON RAPAMYCIN

MIKHAIL BLAGOSKLONNY’S VIEW ON RAPAMYCIN

Scientists are always working towards inventing new things that make life better, longer and interesting. For the incurable diseases, they research relentlessly until they come up with a cure all in the effort of prolonging human life. The real struggle though has been inventing a solution for mortality and there seems to be some light at the end of the tunnel. Since researchers have come up with solutions of close to anything that causes death, now the target has been preventing aging. That means, however old one grows, age may never be a determining factor of one’s death. That way, immortality shall have been achieved for humans!Usually, age comes with certain diseases that in return lead to death. However, researchers have found out that rapamycin an anti aging drug can be used to prolong life and also improve a person’s immunity. In fact, the drug tested on animals proved to prolong the life of rodents.

Mikhail Blagosklonny on his Oncotarget publication, it was believed that aging was a functional decline resulting from molecular damage and could not be prevented. However, Mikhail differs with this theory. He supports the hyper function theory that describes aging as continued growth which can be prevented by use of rapamycin. Combined with other rapalogs in the correct dosage, rapamycin not only prevents disease but also promotes prolonged and healthy life in humans.Rapamycin’s journey began a couple of years ago and its future seems bright since researchers believe it is high time they start using the drug with a focus on aging. In 2006, the drug had been legalized for use in clinics for treatment of various diseases such as cancer and also the diseases that come hand in hand with aging. It was also recommended for use as an anti aging drug and also for transplant patients. A few years later, lots of tests had been done and just affirmed that indeed rapamycin held the future of anti aging therapy.

In his works, oncologist Mikhail argues that although rapamycin prolongs the lifespan of people, it doesn’t make much difference since finally, the person will die. According to him, the drug prolongs life, yes, but again prolonging life means delaying the diseases that come as a result of aging. Therefore, the cause of the death is all but the same. He adds that gerontologists should research on something else such as the potential causes of post aging given that rapamycin is already in clinics. Mikhail further argues that combining various anti aging drugs available in clinics and giving them in correct dosages and schedules is the best way to see maximum life span extension.Mikhail Blagosklonny is not only a researcher but also a professor and philanthropist who believes in fair treatment of all people regardless of their social status. His areas of interest in research are cancer and aging. His hope is to figure out a way of treating cancer patients effectively without destroying other crucial body cells at a cost friendly price.

Omar Boraie Chair at Rutgers to Help Propel Groundbreaking Research

Making contributions to propel never-before-seen research when it comes to the field of cutting-edge medicine at the Rutgers Cancer Institute which is located in New Jersey. Omar Boraie was recently awarded a newly-appointed chair that was named in his honor. Named the Omar Boraie Chair in Genomic Science, this endowed chair is considered the gold standard in higher education. It also expresses the commitment of a university to concentrate on an academic discipline at the highest levels to ensure its continued progression and support.

According to Yahoo.com, New Brunswick developer Omar Boraie was included in the 18 Chair Challenge, where an anonymous donor must match a $1.5 million support campaign at Rutgers University. The university formed 18 new chairs which included the New Jersey developer. The new Omar Boraie chair will help carve a new path for new discoveries in precision medicine and genomic science.

A Growing Field of Study

The field of genomic science and precision medicine has made profound changes on how professionals who work in the medical field approach how cancer is diagnosed and treated. This field is relatively new says the NY Times and involves tumor analysis and treatment using techniques that give doctors that opportunity to help patients at the genetic level. These analyses and treatments allow doctors to prescribe therapies that are individualized for each patient which result in better outcomes.

Rutgers at the Forefront

As one of the first medical treatment centers in the country as well as New Jersey to apply for genomic sequencing as a primary approach to patient care, Rutgers Cancer Institute remains a leader in performing advanced gene sequencing on tumors as a part of ongoing research at the university. For those who have rare cancer diseases or poor prognoses will highly benefit from this research. In addition, many people have treatment options which have been infected or limited, so genomic sequencing has been extremely helpful in finding unique therapies that were not available to patients with such circumstances in the past.

Recently Quoted on Newswise

In a recent article from Newswise (http://newswise.com/articles/omar-boraie-chair-in-genomic-science-established-at-rutgers-cancer-institute), Omar Boraie mentioned that physicians and scientists at Rutgers Cancer Institute are making huge advances precision medicine, especially for patients who are suffering from cancers that are no longer responsive. He also expressed that he is hopeful that the money he put forward will help others. In addition, he encouraged others to become an anonymous donor for the 18 Chair Challenge. He also hopes his family’s pledge to support the Rutgers Cancer Institute will inspire others to contribute as well. Boraie has been a long supporter of cancer research and this endowment furthers his vision to develop New Brunswick into a “Healthcare City”.

Reference: http://www.njbiz.com/article/20141230/NJBIZ01/141239989/the-visionary-omar-boraie-has-seen-the-potential-of-new-brunswick-for-four-decades